Innovative radioisotope therapy for patients with neuroendocrine tumors using an α (225Ac) emitter labeled somatostatin analog: octreotate. A promising new treatment for advanced progressive neuroendocrine neoplasms.

Authors :: Budlewski T
Król ZJ
Bruchertseifer F
Majkowska-Pilip A
Morgenstern A
Wierzba W
Source :: Polish archives of internal medicine [Pol Arch Intern Med] 2022 Aug 22; Vol. 132 (7-8). Date of Electronic Publication: 2022 Jun 13.
Publication Year :: 2022

Subjects :: Actinium
Humans
Radioisotopes
Somatostatin therapeutic use
Neuroendocrine Tumors radiotherapy

Full Text Access

Tools